Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 5.3% - What's Next?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) traded down 5.3% during mid-day trading on Monday . The stock traded as low as $0.31 and last traded at $0.32. 28,828,476 shares changed hands during trading, a decline of 5% from the average session volume of 30,399,371 shares. The stock had previously closed at $0.34.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a research report on Monday, December 23rd. They set a "hold" rating on the stock.

Tonix Pharmaceuticals Stock Up 6.6 %

The firm has a market cap of $67.28 million, a price-to-earnings ratio of -0.01 and a beta of 2.23. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The firm has a 50 day moving average price of $0.22 and a 200-day moving average price of $0.38.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.82 million during the quarter, compared to analysts' expectations of $2.63 million. As a group, equities analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.